Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 30 to 75 at the time of screening visit~* Subjects with type 2 DM diagnosed for at least 3 months before screening~* Subjects with type 2 DM treated with monotherapy of 500mg ≤ metformin ≤ 1000mg for at lest 4 weeks prior to screening~* HbA1c ≥ 7.0% but ≤ 10.0% at the time of screening visit~* 21 kg/m2 ≤ BMI ≤ 40 kg/m2~* A negative pregnancy test for all females of childbearing potential~* Provision of signed and dated informed consent prior to any study procedures~* Ability and willingness to perform SMBG and record the data on the subject's diary~Exclusion Criteria:~* A history of acute metabolic complications such as diabetic ketoacidosis or hyperosmolar nonketotic coma within 3 months before screening~* Current therapy with anti-hyperglycemic agents (except metformin) use in the 4 weeks (8 weeks in case of thiazolidinedione) before screening~* Concomitant treatment prohibited during the study period~  * Any oral hypoglycemic agent other than glimepiride, metformin HCl, and fixed-dose combination of glimepiride and metformin HCl~ * Any insulin therapy over 7 days consecutively or intermittently in order to treat acute metabolic decompensation or systemic infection during the study~ * Intermittent use of systemic corticosteroids or large dose of inhaled steroids~* Subjects with clinically significant renal (serum creatinine level \> 1.5 mg/dL in male and \> 1.4 mg/dL in female) or hepatic disease (ALT and AST \> 2x ULN)~* Clinically significant laboratory abnormality on screening labs or any medical condition that would affect the completion or outcome of the study in the opinion of the investigator and/or sponsor;~* Pregnant or lactating females~* History of drug or alcohol abuse~* Subjects who have a history of noncompliance with regards to follow-up medical care~* Subjects with known hypersensitivity to glimepiride, metformin HCL~* Night-shift workers~* Treatment with any investigational product in the last 3 months before study entry~* Others; subjects who have participated in this study

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Amaryl M group
- 2 (Type: ACTIVE_COMPARATOR): Metformin group

Based on this trial design, predict the completion outcome and termination type (if applicable).